Development of CIRC Technologies

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThe Cleveland Clinic

About this trial

Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow us the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.

Our team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.

Eligibility criteria

Qualifiers

Age ≥ 18 years of age

Provision of written informed consent

If not healthy volunteer, must be diagnosed with cardiovascular disease

Disqualifiers

Vulnerable populations will be excluded from this study including Prisoners

Other contraindications to CMR imaging to be determined by standard MRI protocols

Decisionally impaired (e.g., dementia or cognitive disability)

Trial design

Treatments tested in this trial

  • MRI

Treatment groups

1,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators